Morphic announces participation in cowen 42nd annual healthcare conference

Waltham, mass., march 04, 2022 (globe newswire) -- morphic therapeutic (nasdaq: morf), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced morphic president and ceo praveen tipirneni, m.d. will participate in a gastrointestinal and microbiome virtual panel discussion at the 42nd annual cowen healthcare conference at 10:30 am et on wednesday, march 9th.
MORF Ratings Summary
MORF Quant Ranking